Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11019221 | Nutrition Clinique et Métabolisme | 2018 | 7 Pages |
Abstract
Short bowel syndrome (SBS) occurs when a patient is left with less than 200Â cm of functional small intestine. Drug absorption is mostly a passive process and can be affected by the surface area of the remaining gastrointestinal tract. Oral medication absorption is often impaired and larger doses, or other administration routes may be required. Although patients with SBS do need pharmacotherapy for symptoms associated with their pathology or for other comorbidities, there are few published case reports on drug absorption, and few studies have been conducted in small patients' samples. Moreover, due to the highly heterogeneous nature of this patient population, it is difficult to directly apply the findings of the published literature to specific patients. Drug dosages should be guided by the monitoring of clinical endpoints and/or of biomarkers.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Kuntheavy Ing Lorenzini, Celia Lloret-Linares, Jules Desmeules, Caroline Samer,